Bireociclib

吡洛西利

Report date: 2026/04/15 13:56:52
NME

Base Information

Drug NameBireociclib
Drug Alias Namebireociclib吡罗西尼Birociclib轩悦宁XZP-3287
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionCyclin-dependent kinase 6 inhibitorsCyclin-dependent kinase 4 inhibitorsCyclin-dependent kinase 2 inhibitors +[4] 
TargetsCyclin-dependent kinase 6Cyclin-dependent kinase 4Cyclin-dependent kinase 2 +[4] 
Therapy Area/IndicationsMetastatic breast cancerSolid tumoursProstatic Neoplasms +[4] 
Global Approved IndicationsMetastatic breast cancerBreast Neoplasms
Approved Indications in ChinaMetastatic breast cancerBreast Neoplasms
Original Approved Country/TerritoryMainland China
Original Approved Date2025/05/13
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesShandong Xuanzhu Pharmaceutical Technology Co LtdSihuan Pharmaceutical Holdings Group Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesBoston Oncology CGT Holding Co ltdShandong Xuanzhu Pharmaceutical Technology Co LtdSihuan Pharmaceutical Holdings Group Ltd +[6] 
Inactive CompaniesN/A
Active IndicationsMetastatic breast cancerSolid tumoursProstatic Neoplasms +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A